• CROSSJECT unveils its strategic choices and new roadmap

    - Priority given to emergency treatment drugs
    - Priority focus on penetrating the US market
    - Capitalisation on a first-class industry partnership with CENEXI and internalisation of certain manufacturing operations
    - Revision of regulatory timetable: Approval to Market applications filed for 6 products in 2018

    Read the Press release

    Read more
  • Crossject - AFPric study: patients approve needle-free injection

    Crossject and AFPric, the largest French association of patients with polyarthritis and chronic inflammatory rheumatisms, pursued their collaboration and released today the main findings of a study conducted with members of AFPric on their treatment and their interest in needle-free injection. 

    The study reveals that patients with rheumatoid polyarthritis are largely prepared to use needle-free injection as part of their treatment. 85.9% of respondents are ready to use a needle-free injection device, three quarters of which are currently taking their treatment with injection 

    Read the press release

    Read more


  • 07/01/2016

    Crossject will be present at BioPharm America 2016

    Crossject will be present at BIOPHARM AMERICA 2016, the 9th Annual International Partnering Conference, September 13 to 15. BIOPharm America™ is where biotech industry partnerships get started, with biotech and pharma executives from around the world. Close to 900 attendees are expected to participate in this Conference.
    Contact Tim Muller: or  / Mobile +33 (0)645523540 / skype id: timotheemuller

    Read more
  • 08/01/2014

    Crossject will be present at EuroPLX 62 Nice

    Meet us in Nice, November 21th and 22nd, during the Pharma Event EuroPLX.
    Contact Tim Muller: or  / Mobile +33 (0)645523540 / skype id: timotheemuller

    Read more


Discover our needle-free self injectable solution

The desire for safer and more user-friendly injection device to prevent needle-stick injuries...

more videos